Clinical Trial Update: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy (ANTLER) for relapsed/refractory B-cell non-Hodgkin lymphoma. The study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CRISPR-edited allogeneic anti-CD19 CAR-T

Snippet

Sponsor: Caribou Biosciences, Inc. | Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma | Phase 1 | Status: RECRUITING